The NCCTG Statistical/Data Management Office provides statistical collaboration and data management support for NCCTG clinical trials, translational, and related research activities. The office has a long history of statistical and technological innovation with the goal of improving the conduct of clinical trial design, monitoring, and analysis. Recently, statistical research has focused on refining and simplifying methods for assessing patient quality of life, developing survival analysis methods for multiple event data and meta analyses, and investigating novel designs for phase II clinical trials. In addition, statistical personnel have assumed the principal investigator role on selected recent clinical studies. Throughout the unit's history, a focus has been on developing and implementing systems that incorporate quality control into all aspects of study development and conduct. Recently, these efforts have focused on harnessing the power of the Internet to improve the data quality and efficiency of clinical trials. The data management office has developed and is in the process of implementing several web-based systems, including remote registration/randomization and remote data entry. When fully implemented during the proposed grant period, these systems will allow greater efficiency both at the NCCTG Research Base and at NCCTG member institutions. NCCTG forms have been radically redesigned to allow increased flexibility and efficiency. Data elements have been reduced substantially to eliminate unnecessary items. Additionally, we have developed automated quality control editing programs with both within-form and between-form consistency and integrity checks, thus reducing the manual effort required to assure the highest quality data. We have developed a database that allows substantial flexibility to manage non-traditional datatypes. As the NCCTG moves forward into new and expanding areas of emphasis, such as translational research, novel therapeutics, genetic epidemiology, and quality of life issues, the Statistical/Data Management Office has demonstrated the ability to continue to evolve to provide the highest level of collaboration for NCCTG clinical investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA025224-23
Application #
6563787
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-01-11
Project End
2002-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
23
Fiscal Year
2002
Total Cost
$78,870
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506
Schiff, David; Jaeckle, Kurt A; Anderson, S Keith et al. (2018) Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. Cancer 124:1455-1463
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Witzig, T E; LaPlant, B; Habermann, T M et al. (2017) High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J 7:e576
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060

Showing the most recent 10 out of 718 publications